Basic Information
| LncRNA/CircRNA Name | XIST |
| Synonyms | XIST, DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66 |
| Region | GRCh38_X:73820651-73852753 |
| Ensemble | ENSG00000229807 |
| Refseq | NR_001564 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown etc. |
| Sample | cell lines (5637, T24) |
| Expression Pattern | up-regulated |
| Function Description | lncRNA XIST possesses the reverse function in bladder cancer cells.miR-200c overexpression and XIST knockdown could inhibit cell clone formation, self-renewal ability and EMT in BCSC-like cells. miR-200c knockdown could restore the tumour growth inhibition caused by XIST knockdown. |
| Pubmed ID | 29559853 |
| Year | 2018 |
| Title | LncRNA XIST/miR-200c regulates the stemness properties and tumourigenicity of human bladder cancer stem cell-like cells. |
External Links
| Links for XIST | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |